February 26, 2018 / 8:07 PM / 6 months ago

BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer

Feb 26 (Reuters) - Tesaro Inc:

* TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER

* TESARO INC - ‍PLANNED TRIAL WILL BE CONDUCTED BY GENENTECH AND IS EXPECTED TO BEGIN MID-2018​

* TESARO INC - ‍COLLABORATION INCLUDES TESTING EXPERIMENTAL COMBINATION IN MORPHEUS, ROCHE’S CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below